Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 16/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124223 | 0.87 | CHRNA7 (0.36) | CHRNA7F10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7121696 | 0.85 | CHRNA7 (0.35) | CHRNA7F10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7224323 | 0.85 | MEN1 (0.38) | F10F2 | |
| SCHEMBL7124013 | 0.85 | EPHX2 (0.36) | CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7127427 | 0.85 | F10 (0.38) | CHRNA7F10TRPV1SLC6A2SLC6A4 | |
| SCHEMBL7125381 | 0.85 | CHRNA7 (0.35) | CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7120663 | 0.85 | SLC6A2 (0.38) | CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7123508 | 0.84 | TRPV1 (0.44) | CHRNA7F10TRPV1SLC6A4SLC6A3 | |
| SCHEMBL7113625 | 0.84 | CHRNA7 (0.36) | CHRNA7TRPV1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7120734 | 0.84 | GAA (0.35) | CHRNA7SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | CHRNA7 397/4885F10 4216/4885F2 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.